Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 3/20 | 0.56 |
| ▸ | KYAT1 | Q16773 | 2/20 | 0.56 |
| ▸ | KYAT3 | Q6YP21 | 2/20 | 0.56 |
| ▸ | GOT1 | P17174 | 1/20 | 0.56 |
| ▸ | PYGL | P06737 | 13/20 | 0.44 |
| ▸ | PYGM | P11217 | 11/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763198 | 0.81 | AADAT (0.49) | AADATKYAT1KYAT3GOT1PYGL | |
| SCHEMBL3768775 | 0.81 | AADAT (0.67) | AADATKYAT1KYAT3GOT1 | |
| SCHEMBL1290127 | 0.80 | AADAT (0.44) | AADATKYAT1KYAT3GOT1PYGL | |
| SCHEMBL4800980 | 0.80 | PYGL (0.43) | AADATPYGLPYGM | |
| SCHEMBL4800991 | 0.80 | PYGL (0.43) | AADATPYGLPYGM | |
| SCHEMBL3786143 | 0.80 | AADAT (0.42) | AADATKYAT1KYAT3GOT1 | |
| SCHEMBL25329972 | 0.78 | OPRM1 (0.45) | PYGLPYGM | |
| SCHEMBL4486212 | 0.78 | ACE (0.45) | PYGLPYGM | |
| SCHEMBL7695914 | 0.78 | ACE (0.45) | MTNR1AMTNR1B | |
| SCHEMBL3773883 | 0.77 | RIPK1 (0.38) | AADATMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443092-B1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | AADAT 2284/4885KYAT1 69/4885KYAT3 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.